These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 17552024)

  • 1. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy.
    Le Guillou-Guillemette H; Vallet S; Gaudy-Graffin C; Payan C; Pivert A; Goudeau A; Lunel-Fabiani F
    World J Gastroenterol; 2007 May; 13(17):2416-26. PubMed ID: 17552024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C virus: How genetic variability affects pathobiology of disease.
    Chayama K; Hayes CN
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():83-95. PubMed ID: 21199518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
    Morishima C; Polyak SJ; Ray R; Doherty MC; Di Bisceglie AM; Malet PF; Bonkovsky HL; Sullivan DG; Gretch DR; Rothman AL; Koziel MJ; Lindsay KL;
    J Infect Dis; 2006 Apr; 193(7):931-40. PubMed ID: 16518754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
    Wyles DL; Gutierrez JA
    J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T; Hueppe D; Mauss S; Buggisch P; Pfeiffer-Vornkahl H; Grimm D; Galle PR; Alshuth U
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
    Toyoda H; Kumada T; Tada T; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Jul; 83(7):1203-11. PubMed ID: 21567424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can genetic variations predict HCV treatment outcomes?
    Selzner N; McGilvray I
    J Hepatol; 2008 Oct; 49(4):494-7. PubMed ID: 18692270
    [No Abstract]   [Full Text] [Related]  

  • 10. Secondary structure of the amino-terminal region of HCV NS3 and virological response to pegylated interferon plus ribavirin therapy for chronic hepatitis C.
    Sanjo M; Saito T; Ishii R; Nishise Y; Haga H; Okumoto K; Ito J; Watanabe H; Saito K; Togashi H; Fukuda K; Imai Y; El-Shamy A; Deng L; Shoji I; Hotta H; Kawata S
    J Med Virol; 2010 Aug; 82(8):1364-70. PubMed ID: 20572079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
    Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
    Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
    Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2009 Mar; 81(3):459-66. PubMed ID: 19152412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amino acid sequence analysis in patients with chronic HCV genotype 1b infection during pegylated interferon-α2a and ribavirin therapy.
    Fu JJ; Kong WJ; Jiang D; Pan XC; Wei L
    Antivir Ther; 2014; 19(7):661-8. PubMed ID: 24584067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
    Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
    World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.
    Galán RJ; Cidoncha EC; Martin MF; Rodriguez CC; Almeida CV; Verdugo RM
    J Manag Care Pharm; 2013; 19(6):448-53. PubMed ID: 23806058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus.
    Soria ME; Gregori J; Chen Q; García-Cehic D; Llorens M; de Ávila AI; Beach NM; Domingo E; Rodríguez-Frías F; Buti M; Esteban R; Esteban JI; Quer J; Perales C
    BMC Infect Dis; 2018 Sep; 18(1):446. PubMed ID: 30176817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals.
    Serfaty L
    Liver Int; 2015 Jan; 35 Suppl 1():18-20. PubMed ID: 25529083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal therapy in genotype 1 patients.
    Farnik H; Mihm U; Zeuzem S
    Liver Int; 2009 Jan; 29 Suppl 1():23-30. PubMed ID: 19207963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.